Patents by Inventor Jiaming Yan

Jiaming Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS
    Publication number: 20230399324
    Abstract: The present disclosure relates to 1,4-benzothiazepine derivatives and use thereof to treat conditions associated with ryanodine receptors that regulate calcium channel functioning in cells.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 14, 2023
    Inventors: Sandro BELVEDERE, Jiaming YAN
  • Process for preparing benzothiazepines from gamma-aminoalkylbenzenes
    Patent number: 9573914
    Abstract: The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 21, 2017
    Assignees: LES LABORATOIRES SERVIER, ARMGO Pharma, Inc.
    Inventors: Shixian Deng, Sandro Belvedere, Jiaming Yan, Donald Landry
  • AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS
    Publication number: 20140378437
    Abstract: The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 25, 2014
    Inventors: JIAMING YAN, SANDRO BELVEDERE, YAEL WEBB, MARC BERTRAND, NICOLE VILLENEUVE
  • Agents for treating disorders involving modulation of ryanodine receptors
    Patent number: 8853198
    Abstract: The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: October 7, 2014
    Assignees: Les Laboratoires Servier, ARMGO Pharma, Inc.
    Inventors: Jiaming Yan, Sandro Belvedere, Yael Webb, Marc Bertrand, Nicole Villeneuve
  • PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES
    Publication number: 20140121368
    Abstract: The invention provides a process for preparing a 2,3,4,5-tetrahydro[1.4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
    Type: Application
    Filed: December 23, 2013
    Publication date: May 1, 2014
    Applicants: ARMGO PHARMA, INC., LES LABORATOIRES SERVIER
    Inventors: Shixian DENG, Sandro BELVEDERE, Jiaming YAN, Donald LANDRY
  • AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS
    Publication number: 20140088171
    Abstract: The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
    Type: Application
    Filed: November 11, 2013
    Publication date: March 27, 2014
    Applicants: ARMGO PHARMA, INC., LES LABORATOIRES SERVIER
    Inventors: JIAMING YAN, SANDRO BELVEDERE, YAEL WEBB, MARK BERTRAND, NICOLE VILLENEUVE
  • Process for preparing benzothiazepines from gamma-aminoalkylbenzenes
    Patent number: 8618282
    Abstract: The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: December 31, 2013
    Assignee: Les Laboratoires Servier
    Inventors: Shixian Deng, Sandro Belvedere, Jiaming Yan, Donald Landry
  • AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS
    Publication number: 20130281512
    Abstract: The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
    Type: Application
    Filed: April 18, 2013
    Publication date: October 24, 2013
    Applicants: ARMGO Pharma, Inc., LES LABORATOIRES SERVIER
    Inventors: Jiaming YAN, Sandro BELVEDERE, Yael WEBB, Mark BERTRAND, Nicole VILLENEUVE
  • Histone deacetylase inhibitors
    Patent number: 7795304
    Abstract: The invention relates to hydroxamic acid derivatives having carbamate linkage with the structural formula that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous systems (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: September 14, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sandro Belvedere, Christopher Laurence Hamblett, Thomas A. Miller, David J. Witter, Jiaming Yan
  • Histone deacetylase inhibitors
    Patent number: 7737184
    Abstract: This invention relates to hydroxamic acid derivatives having a urea linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: June 15, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sandro Belvedere, Christopher Laurence Hamblett, Thomas A. Miller, David J. Witter, Jiaming Yan
  • PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES
    Publication number: 20090227788
    Abstract: The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
    Type: Application
    Filed: March 3, 2009
    Publication date: September 10, 2009
    Inventors: Shixian Deng, Sandro Belvedere, Jiaming Yan, Donald Landry
  • Histone deacetylase inhibitors
    Patent number: 7534918
    Abstract: This invention relates to hydroxamic acid derivatives having a sulfonamide linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: May 19, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Sandro Belvedere, Joey Lee Methot, Thomas A. Miller, David J. Witter, Jiaming Yan
  • Histone deacetylase inhibitors
    Publication number: 20090118291
    Abstract: This invention relates to hydroxamic acid derivatives having a carbamate linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Application
    Filed: August 22, 2005
    Publication date: May 7, 2009
    Inventors: Sandro Belvedere, Christopher Laurence Hamblett, Thomas A. Miller, David J. Witter, Jiaming Yan
  • Histone Deacetylase Inhibitors
    Publication number: 20080033015
    Abstract: This invention relates to hydroxamic acid derivatives having a urea linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Application
    Filed: July 8, 2005
    Publication date: February 7, 2008
    Inventors: Sandro Belvedere, Christopher Hamblett, Thomas Miller, David Witter, Jiaming Yan
  • Histone Deacetylase Inhibitors
    Publication number: 20080015216
    Abstract: This invention relates to hydroxamic acid derivatives having a sulfonamide linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Application
    Filed: July 8, 2005
    Publication date: January 17, 2008
    Inventors: Sandro Belvedere, Joey Lee Methot, Thomas Miller, David Witter, Jiaming Yan